In addition, anti-angiogenic agents like bevacizumab, a targeted vascular endothelial growth factor (VEGF) inhibitor, have shown the ability to disrupt tumor vasculature, thereby inhibiting tumor growth and metastasis [21,22,23]. This evidence concerns the gene VEGFA and neoplasm.